Validation of a therapeutic scheme for the treatment of resistant hypertension

Journal of the American Society of Hypertension

Volumn 5, Issue 6, 2011, Pages 498-504

  Segura, Julian ^a   Cerezo, Cesar ^a   Garcia Donaire, Jose A ^a   Schmieder, Roland E ^b   Praga, Manuel ^a   De La Sierra, Alejandro ^c   Ruilope, Luis M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

ambulatory blood pressure measurement; blood pressure control; direct renin inhibition; resistant hypertension; spironolactone

Indexed keywords

ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; RENIN; RENIN INHIBITOR; SPIRONOLACTONE;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADULT; AGED; AMBULATORY MONITORING; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; COMORBIDITY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; FEMALE; GYNECOMASTIA; HUMAN; HYPERKALEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SIDE EFFECT; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; VALIDATION PROCESS;

AGED; AMIDES; AMLODIPINE; CALCIUM CHANNEL BLOCKERS; CHLORTHALIDONE; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; FUMARATES; FUROSEMIDE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENIN; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 81255134295     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2011.08.003     Document Type: Article

References (32)

1. D.A. Calhoun, D. Jones, S. Textor, D.C. Goff, T.P. Murphy, and R.D. Toto Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Hypertension 51 2008 1403 1419
2. P.A. Sarafidis, and G.L. Bakris Resistant hypertension: an overview of evaluation and treatment J Am Coll Cardiol 52 2008 1749 1757
3. J. Redon, C. Campos, M.L. Narciso, J.L. Rodicio, J.M. Pascual, and L.M. Ruilope Prognostic value of ambulatory blood pressure monitoring in refractory: a prospective study Hypertension 31 1998 712 718
4. A. De la Sierra, J. Segura, J.R. Banegas, M. Gorostidi, J.J. de la Cruz, and P. Armario Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring Hypertension 57 2011 898 902
5. F. de Souza, E. Muxfeldt, R. Fiszman, and G. Salles Efficacy of spironolactone therapy in patients with true resistant hypertension Hypertension 55 2010 147 152
6. B. Alvarez-Alvarez, M. Abad-Cardiel, A. Fernandez-Cruz, and N. Martell-Claros Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system J Hypertens 28 2010 2329 2335
7. M. Engbaek, M. Hjerrild, J. Hallas, and I.A. Jacobsen The effect of low-dose spironolactone on resistant hypertension J Am Soc Hypertens 4 2010 290 294
8. M.A. Weber, H. Black, G. Bakris, H. Krum, S. Linas, and R. Weiss A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial Lancet 374 2009 1423 1431
9. X. Jeunemaitre, G. Chatellier, C. Kreft-Jais, A. Charru, C. DeVries, and P.F. Plouin Efficacy and tolerance of spironolactone in essential hypertension Am J Cardiol 60 1987 820 825
10. G.P. Rossi, A.C. Pessina, and A.M. Heagerty Primary aldosteronism: an update on screening, diagnosis and treatment J Hypertens 26 2008 613 621
11. G.P. Rossi, T.M. Seccia, and A.C. Pessina Primary aldosteronism - part I: prevalence, screening, and selection of cases for adrenal vein sampling J Nephrol 21 2008 447 454
12. M.C. Acelajado, and D.A. Calhoun Aldosteronism and resistant hypertension Int J Hypertens 2011 article ID 837817
13. K. Gaddam, C. Corros, E. Pimenta, M. Ahmed, T. Denney, and I. Aban Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study Hypertension 55 2010 1137 1142
14. J.R. Sowers, A. Whaley-Connell, and M. Epstein Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension Ann Intern Med 150 2009 776 783
15. G. Parati, H. Schumacher, G. Bilo, and G. Mancia Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database J Hypertens 28 2010 2177 2183
16. M. Haria, and A.J. Wagstaff A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease Drugs 50 1995 560 586
17. A.J. Webb, U. Fischer, Z. Mehta, and P.M. Rothwell Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis Lancet 375 2010 906 915
18. K. Jamerson, M.A. Weber, G.L. Bakris, B. Dahlöf, B. Pitt, V. Shi ACCOMPLISH Trial Investigators Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients N Engl J Med 359 2008 2417 2428
19. G.L. Bakris, P.A. Sarafidis, M.R. Weir, B. Dahlöf, B. Pitt, K. Jamerson ACCOMPLISH Trial investigators Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial Lancet 375 2010 1173 1181
20. M.E. Ernst, B.L. Carter, S. Zheng, and R.H. Grimm Jr. Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium Am J Hypertens 23 2010 440 446
21. M.P. Dorsch, B.W. Gillespie, S.R. Erickson, B.E. Bleske, and A.B. Weder Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis Hypertension 57 2011 689 694
22. M.E. Ernst, B.L. Carter, C.J. Goerdt, J.J. Steffensmeier, B.B. Phillips, and M.B. Zimmerman Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure Hypertension 47 2006 352 358
23. K. Andersen, M.H. Weinberger, B. Egan, C.M. Constance, M.A. Ali, and J. Jin Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial J Hypertens 26 2008 589 599
24. K. Andersen, M.H. Weinberger, B. Egan, C.M. Constance, M. Wright, and V. Lukashevich Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial Cardiovasc Ther 28 2010 344 349
25. R.E. Schmieder, T. Philipp, J. Guerediaga, M. Gorostidi, B. Smith, and N. Weissbach Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized double-blind comparator trial with hydrochlorothiazide Circulation 119 2009 417 425
26. W. Krone, M. Hanefeld, H.F. Meyer, T. Jung, M. Bartlett, and C.M. Yeh Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome J Hum Hypertens 25 2011 186 195
27. S.T. Duggan, C.M. Chwieduk, and M.P. Curran Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension Drugs 70 2010 2011 2049
28. T.W. Littlejohn 3rd, P. Trenkwalder, G. Hollanders, Y. Zhao, and W. Liao Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension Curr Med Res Opin 25 2009 951 959
29. C.M. Ferrario Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control Life Sci 86 2010 289 299
30. J. Alfie, L.S. Aparicio, and G.D. Waisman Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin- aldosterone system inhibition Rev Recent Clin Trials 6 2011 134 146
31. M.H. Alderman, W.L. Ooi, H. Cohen, S. Madhavan, J.E. Sealey, and J.H. Laragh Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients Am J Hypertens 10 1997 1 8
32. A. Ichihara, M. Sakoda, A. Kurauchi-Mito, T. Narita, K. Kinouchi, and K. Bokuda New approaches to blockade of the renin-angiotensin-aldosterone system: characteristics and usefulness of the direct renin inhibitor aliskiren J Pharmacol. Sci 113 2010 296 300